Versigent (NYSE:VGNT) Announces Quarterly Earnings Results

Versigent (NYSE:VGNT) posted its quarterly earnings data on Tuesday. The company reported $999.00 earnings per share (EPS) for the quarter, Zacks reports.

Here are the key takeaways from Versigent’s conference call:

• Versigent began trading as an independent public company on April 1 and reported a strong Q1 with $2.2B revenue (+9% reported, +3% adjusted) and $203M adjusted EBITDA (9.2%), highlighting >99% quality and on‑time performance on launches.
• The company reaffirmed 2026 guidance of $9.1–$9.4B revenue, $950M–$1.03B adjusted EBITDA (~10.7% margin midpoint) and $200M–$300M free cash flow, citing continued volume ramps and operational initiatives.
• Q1 margins were pressured by commodity and FX moves—copper rose >25% (driving roughly a $46M year‑over‑year hit) and a ~3–4 month pass‑through lag caused ≈50 bps of margin dilution; management expects most of this timing effect to normalize by end‑Q2/start‑Q3 if prices remain stable.
• Book-to-bill momentum was strong with $2.6B of new bookings and 24 new programs (including the first production win in energy storage), supporting expansion into selected non‑automotive adjacencies and APAC growth (+12% adjusted).
• Board approved a shareholder return framework: an initial target dividend of about $0.13 per share per quarter (to be considered after Q2) and a $250M buyback authorization, to be funded opportunistically from operating cash flow.

Versigent Price Performance

Shares of NYSE VGNT traded up $1.31 during trading hours on Tuesday, hitting $37.48. The stock had a trading volume of 1,828,951 shares, compared to its average volume of 3,587,298. Versigent has a 52 week low of $26.34 and a 52 week high of $37.68.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on VGNT. UBS Group began coverage on Versigent in a report on Tuesday, April 14th. They set a “buy” rating and a $43.00 price objective on the stock. Wolfe Research began coverage on Versigent in a report on Thursday, April 30th. They set an “outperform” rating and a $53.00 price objective on the stock. Evercore began coverage on Versigent in a report on Tuesday, April 21st. They set an “outperform” rating and a $55.00 price objective on the stock. Wells Fargo & Company started coverage on Versigent in a report on Monday, April 6th. They set an “overweight” rating and a $35.00 price objective on the stock. Finally, Zacks Research upgraded Versigent to a “hold” rating in a report on Thursday, April 16th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, Versigent presently has a consensus rating of “Moderate Buy” and an average target price of $42.13.